Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vitruviae LLC currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit, reflecting a very narrow prosecution focus. For a company in the biotech sector, this concentration suggests that their current patent activity is confined to a specific technical niche or a single product line within the pharmaceutical field.
The busiest examiner for the portfolio is RONEY, CELESTE A, who is responsible for 1 pending office action. Since the total number of pending actions is 1, this examiner is the sole individual reviewing the company's active applications. This means the company's immediate success in the Biotechnology & Pharmaceuticals field depends on the specific feedback and examination style of RONEY, CELESTE A. Practitioners should focus their efforts on this 1 distinct examiner, as no other art units are currently involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RONEY, CELESTE A | 1 | 62.8% | +17.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022087 | Vaccine Compositions and Antibodies For Lyme Disease | RONEY, CELESTE A | 1d overdue |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18022087 | Vaccine Compositions and Antibodies For Lyme Disease | RONEY, CELESTE A | 1612 | §103 | Non-Final OA | 1d overdue | Pending | Feb 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial